- 1,489studies on this subject, of 27,380 in the library
- 1,432peer-reviewed
- 1986–2026years published
- 50median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news. How we score a study. For a plain-English guide to this subject, see Treatments.
The 20 highest-scoring studies
- Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis
- Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study
- Japanese participant data from three gantenerumab trials in early Alzheimer's disease
- Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis
- TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
- Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis
-
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
In two large phase 3 trials, the anti-amyloid antibody bapineuzumab given to people with mild-to-moderate Alzheimer's disease produced no significant difference from placebo on the main measures of cognition and daily function. This means the drug did not work as hoped in these patients, and it is not a treatment for Alzheimer's disease.
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease
- Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
- Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease
- Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial
- Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis
- Systematic Review of Sex-Specific Reporting of Data: Cholinesterase Inhibitor Example
-
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
This analysis of donanemab trials found that amyloid-related imaging abnormalities (ARIA) are an adverse event associated with donanemab treatment that requires safety monitoring. Several baseline factors were linked to higher or lower risk of ARIA-E.
-
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
This report describes amyloid-related imaging abnormalities in two phase 3 studies of aducanumab in people with early Alzheimer disease. The provided text does not include information on whether aducanumab affected cognitive or functional outcomes.
-
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease
This trial tested verubecestat, a BACE-1 inhibitor that blocks production of amyloid-beta, in patients with prodromal Alzheimer's disease. The drug did not prevent clinical progression in an earlier trial involving patients with mild-to-moderate dementia due to Alzheimer's disease.
- Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials
- Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab
- The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis
- Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis
See all 1,489 studies in Treatments, with filters →
Newest additions on this subject
- Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions
- Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling
- Mapping post-translational modifications across amyloid-β deposits in Alzheimer’s disease: A neuropathologic survey with in vitro functional analysis of nitration
- Simulating the Effects of Gamma Oscillation Treatment on Selective Neurotransmitters Using The Virtual Brain and Complex Pathway Simulator
- Substituent Effects on Electronic Properties and Acetylcholinesterase Inhibitory Potential of Donepezil Analogues: A DFT, Molecular Docking, and ADMET Study with Dynamics Validation of the Lead Candidate
- Docking-Guided Design and Biological Evaluation of a Lead Convolvine-Based Acetylcholinesterase Inhibitor for Alzheimer's Disease
- APOE ε4 Carrier Status and Cognitive Decline in Mild-to-Moderate Alzheimer’s Disease: A Linear Mixed-Effects Analysis of the Placebo Arm of EXPEDITION 1
- In silico design and physicochemical characterisation of a dual-action intranasal nanoparticle formulation for Alzheimer’s disease
- Cognition in Cardiovascular Disease
- Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic
All 1,489 studies in Treatments, newest first →
What the library holds on this subject
By review status
| Status | Studies |
|---|---|
| Peer-reviewed | 1,432 |
| Preprint — not yet peer-reviewed | 47 |
| Press release — not a study | 1 |
| Regulatory decision — not a study | 7 |
| Retracted — do not rely on it | 2 |
By strength of evidence
| Rated in our summary | Studies |
|---|---|
| high | 706 |
| low | 679 |
| moderate | 91 |
| not rated | 5 |
| early | 4 |
| null-result | 3 |
| preliminary | 1 |
Most frequent journals
| Journal | Studies |
|---|---|
| Neurology | 73 |
| Journal of Alzheimer's disease : JAD | 44 |
| The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry | 42 |
| JAMA neurology | 34 |
| The journal of prevention of Alzheimer's disease | 32 |
| Alzheimer disease and associated disorders | 31 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 31 |
| Alzheimer's research & therapy | 30 |
| Archives of neurology | 30 |
| JAMA | 25 |
Studies by year published
| Year | Studies | Bar |
|---|---|---|
| 2026 | 123 | |
| 2025 | 213 | |
| 2024 | 103 | |
| 2023 | 104 | |
| 2022 | 72 | |
| 2021 | 67 | |
| 2020 | 55 | |
| 2019 | 46 | |
| 2018 | 54 | |
| 2017 | 45 | |
| 2016 | 35 | |
| 2015 | 48 | |
| 2014 | 35 | |
| 2013 | 38 | |
| 2012 | 39 | |
| 2011 | 36 | |
| 2010 | 40 | |
| 2009 | 32 | |
| 2008 | 38 | |
| 2007 | 34 | |
| 2006 | 40 | |
| 2005 | 30 | |
| 2004 | 24 | |
| 2003 | 30 | |
| 2002 | 22 | |
| 2001 | 18 | |
| 2000 | 17 | |
| 1999 | 14 | |
| 1998 | 8 | |
| 1997 | 5 | |
| 1996 | 7 | |
| 1995 | 1 | |
| 1994 | 3 | |
| 1993 | 3 | |
| 1992 | 5 | |
| 1990 | 2 | |
| 1989 | 1 | |
| 1988 | 1 | |
| 1986 | 1 |
Counts the 1,489 studies with a usable publication date. The library is a large sample of published work, not a complete index, so these counts describe the library, not the whole field.
Other subjects in the library
- Getting a diagnosis
- Biomarkers
- Clinical trials
- Prevention and risk
- Caregiving
- How common it is
- Costs and economics
- Genetics
- Laboratory science
- Disease mechanisms
- Vascular contributions
- Prevention trials
- Clinical safety
- Health systems and care delivery
- End-of-life care
- Risk factors
- Digital health tools
- Disparities
- Mild cognitive impairment
- Risk genes beyond APOE
- Brain scans and imaging
- TREM2 and immune genetics
- Cognitive tests and assessment
- Lewy body dementia
- Down syndrome and Alzheimer's
- Long-term cohort studies
- Inflammation and the immune system
- Tau biomarkers
- Brain tissue and pathology
- Drug development
- Hippocampus size on brain scans